Moderna: Q1 Earnings Snapshot – Image for illustrative purposes only (Image credits: Pexels)
Cambridge, Mass. – Investors tracking Moderna’s pivot from pandemic highs received a mixed but encouraging signal as the biotechnology firm delivered first-quarter revenue well above expectations, fueled by robust international COVID-19 vaccine demand. The results highlighted ongoing cost discipline and pipeline advances, even as a major litigation settlement dragged net profits deeper into the red. Shares climbed nearly 5% in premarket trading following the disclosure.[1][2]
Key Financial Metrics Show Revenue Strength
Total revenue reached $389 million for the first quarter, marking a sharp increase from $108 million in the year-ago period and surpassing the average analyst forecast of about $224 million compiled by Zacks Investment Research.[2] Net product sales, primarily from COVID vaccines, contributed $352 million, while other revenue added $37 million.
The company posted a GAAP net loss of $1.3 billion, or $3.40 per share, compared with a $1.0 billion loss, or $2.52 per share, in the prior-year quarter. This figure included a $900 million non-recurring charge tied to a patent dispute settlement with Arbutus Biopharma and Genevant Sciences. Adjusted for such costs, losses narrowed to $1.18 per share, outperforming expectations in that metric while the GAAP EPS trailed some estimates.[1]
Operating expenses reflected progress on efficiency efforts. Research and development spending fell 24% to $649 million, driven by reduced clinical and manufacturing costs from completed programs. Selling, general, and administrative expenses dropped 18% to $173 million.
International Markets Fuel the Turnaround
A geographic shift underpinned the revenue surge, with international markets accounting for $311 million, or 80% of the total, versus just $78 million from the U.S. This contrasted sharply with prior patterns where U.S. sales dominated. Strong deliveries under long-term partnerships in the United Kingdom, Canada, and Australia propelled COVID vaccine volumes higher abroad.[1][2]
Cash reserves stood at $7.5 billion as of March 31, down from $8.1 billion at year-end, reflecting investments in pipeline development amid operating losses. The settlement payment, not yet affecting cash, is slated for the third quarter.
- U.S. revenue: $78 million
- International revenue: $311 million
- Net product sales: $352 million (COVID-focused)
- R&D expenses: Down 24% year-over-year
Stakeholders, including shareholders and potential patients, stand to benefit from this international momentum, which signals stabilizing demand outside the saturated U.S. market.
Pipeline Advances and Full-Year Outlook
Moderna maintained its 2026 revenue growth target of up to 10% over 2025 levels, anticipating a more even U.S.-international split at roughly 50-50. Cost of sales guidance includes the $1.8 billion projection with the litigation charge baked in; R&D is set at $3.0 billion and SG&A at $1.0 billion. Capital expenditures will range from $200 million to $300 million, with year-end cash projected at $4.5 billion to $5.0 billion.
Regulatory milestones bolster long-term prospects. The U.S. FDA set an August 5 decision date for the seasonal flu vaccine mRNA-1010. European approvals came for the flu-plus-COVID combo mCOMBRIAX (mRNA-1083) and mNEXSPIKE. Phase 3 trials advanced for norovirus vaccine mRNA-1403, individualized neoantigen therapy intismeran (with Merck), and propionic acidemia treatment mRNA-3927, with data readouts possible later this year.[2]
These developments offer hope for patients with respiratory illnesses, cancers, and rare metabolic disorders, while providing investors a roadmap beyond COVID reliance. For employees and the Cambridge headquarters community, sustained R&D investments underscore commitment amid biotech sector pressures.
As Moderna navigates litigation headwinds and market shifts, the Q1 beat underscores resilience, positioning the firm for measured recovery in a post-pandemic landscape.
